Victor Montal1, Eduard Vilaplana1, Daniel Alcolea1, Jordi Pegueroles1, Ofer Pasternak2, Sofia González-Ortiz3, Jordi Clarimón1, María Carmona-Iragui1, Ignacio Illán-Gala1, Estrella Morenas-Rodríguez1, Roser Ribosa-Nogué1, Isabel Sala1, María-Belén Sánchez-Saudinós1, Maite García-Sebastian4, Jorge Villanúa5, Andrea Izagirre4, Ainara Estanga4, Mirian Ecay-Torres4, Ane Iriondo4, Montserrat Clerigue4, Mikel Tainta4, Ana Pozueta6, Andrea González6, Eloy Martínez-Heras7, Sara Llufriu7, Rafael Blesa1, Pascual Sanchez-Juan6, Pablo Martínez-Lage8, Alberto Lleó1, Juan Fortea9. 1. Memory Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain; Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas (CIBERNED), Spain. 2. Department of Psychiatry, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA; Department of Radiology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. 3. Department of Radiology, Hospital del Mar, Barcelona, Spain. 4. Center for Research and Advanced Therapies and Memory Clinic, Fundacion CITA-Alzheimer Fundazioa, Donostia/San Sebastian, Spain. 5. Center for Research and Advanced Therapies and Memory Clinic, Fundacion CITA-Alzheimer Fundazioa, Donostia/San Sebastian, Spain; Donostia Unit, Osatek SA, Donostia University Hospital, San Sebastian, Spain. 6. Servicio de Neurología, Hospital Universitario Marqués de Valdecilla, Santander, Spain. 7. Center for Neuroimmunology, Hospital Clinic Barcelona, IDIBAPS, Barcelona, Spain. 8. Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas (CIBERNED), Spain; Center for Research and Advanced Therapies and Memory Clinic, Fundacion CITA-Alzheimer Fundazioa, Donostia/San Sebastian, Spain. 9. Memory Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain; Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas (CIBERNED), Spain. Electronic address: jfortea@santpau.cat.
Abstract
INTRODUCTION: Cortical mean diffusivity (MD) and free water fraction (FW) changes are proposed biomarkers for Alzheimer's disease (AD). METHODS: We included healthy control subjects (N = 254), mild cognitive impairment (N = 41), and AD dementia (N = 31) patients. Participants underwent a lumbar puncture and a 3 T magnetic resonance imaging. Healthy control subjects were classified following National Institute on Aging-Alzheimer's Association stages (stage 0, N = 220; stage 1, N = 25; and stage 2/3, N = 9). We assessed the cortical MD, cortical FW, and cortical thickness (CTh) changes along the AD continuum. RESULTS: Microstructural and macrostructural changes show a biphasic trajectory. Stage 1 subjects showed increased CTh and decreased MD and FW with respect the stage 0 subjects. Stage 2/3 subjects showed decreased CTh and increased cortical MD and FW, changes that were more widespread in symptomatic stages. DISCUSSION: These results support a biphasic model of changes in AD, which could affect the selection of patients for clinical trials and the use of magnetic resonance imaging as a surrogate marker of disease modification.
INTRODUCTION: Cortical mean diffusivity (MD) and freewater fraction (FW) changes are proposed biomarkers for Alzheimer's disease (AD). METHODS: We included healthy control subjects (N = 254), mild cognitive impairment (N = 41), and AD dementia (N = 31) patients. Participants underwent a lumbar puncture and a 3 T magnetic resonance imaging. Healthy control subjects were classified following National Institute on Aging-Alzheimer's Association stages (stage 0, N = 220; stage 1, N = 25; and stage 2/3, N = 9). We assessed the cortical MD, cortical FW, and cortical thickness (CTh) changes along the AD continuum. RESULTS: Microstructural and macrostructural changes show a biphasic trajectory. Stage 1 subjects showed increased CTh and decreased MD and FW with respect the stage 0 subjects. Stage 2/3 subjects showed decreased CTh and increased cortical MD and FW, changes that were more widespread in symptomatic stages. DISCUSSION: These results support a biphasic model of changes in AD, which could affect the selection of patients for clinical trials and the use of magnetic resonance imaging as a surrogate marker of disease modification.
Authors: F Sampedro; S Martínez-Horta; J Perez-Perez; A Horta-Barba; J Martin-Lahoz; A Alonso-Solís; I Corripio; B Gomez-Anson; J Kulisevsky Journal: AJNR Am J Neuroradiol Date: 2019-09 Impact factor: 3.825
Authors: Ignacio Illán-Gala; Victor Montal; Sergi Borrego-Écija; Eduard Vilaplana; Jordi Pegueroles; Daniel Alcolea; Belén Sánchez-Saudinós; Jordi Clarimón; Janina Turón-Sans; Nuria Bargalló; Sofía González-Ortiz; Howard J Rosen; Maria Luisa Gorno-Tempini; Bruce L Miller; Albert Lladó; Ricard Rojas-García; Rafael Blesa; Raquel Sánchez-Valle; Alberto Lleó; Juan Fortea Journal: Brain Date: 2019-04-01 Impact factor: 13.501
Authors: McKenna E Williams; Jeremy A Elman; Linda K McEvoy; Ole A Andreassen; Anders M Dale; Graham M L Eglit; Lisa T Eyler; Christine Fennema-Notestine; Carol E Franz; Nathan A Gillespie; Donald J Hagler; Sean N Hatton; Richard L Hauger; Amy J Jak; Mark W Logue; Michael J Lyons; Ruth E McKenzie; Michael C Neale; Matthew S Panizzon; Olivia K Puckett; Chandra A Reynolds; Mark Sanderson-Cimino; Rosemary Toomey; Xin M Tu; Nathan Whitsel; Hong Xian; William S Kremen Journal: Brain Commun Date: 2021-07-23
Authors: Jian W Dong; Ileana O Jelescu; Benjamin Ades-Aron; Dmitry S Novikov; Kent Friedman; James S Babb; Ricardo S Osorio; James E Galvin; Timothy M Shepherd; Els Fieremans Journal: Neurobiol Aging Date: 2020-01-23 Impact factor: 4.673
Authors: Nicholas M Vogt; Jack F Hunt; Nagesh Adluru; Douglas C Dean; Sterling C Johnson; Sanjay Asthana; John-Paul J Yu; Andrew L Alexander; Barbara B Bendlin Journal: Cereb Cortex Date: 2020-05-14 Impact factor: 5.357
Authors: Victor Montal; Eduard Vilaplana; Jordi Pegueroles; Alexandre Bejanin; Daniel Alcolea; María Carmona-Iragui; Jordi Clarimón; Johannes Levin; Carlos Cruchaga; Neill R Graff-Radford; James M Noble; Jae-Hong Lee; Ricardo Allegri; Celeste M Karch; Christoph Laske; Peter R Schofield; Stephen Salloway; Beau Ances; Tammie Benzinger; Eric McDale; Randall Bateman; Rafael Blesa; Raquel Sánchez-Valle; Alberto Lleó; Juan Fortea Journal: Alzheimers Dement Date: 2020-11-16 Impact factor: 21.566
Authors: Ignacio Illán-Gala; Victor Montal; Jordi Pegueroles; Eduard Vilaplana; Daniel Alcolea; Oriol Dols-Icardo; Noemi de Luna; Janina Turón-Sans; Elena Cortés-Vicente; Luis Martinez-Roman; Maria Belén Sánchez-Saudinós; Andrea Subirana; Laura Videla; Isabel Sala; Isabel Barroeta; Sílvia Valldeneu; Rafael Blesa; Jordi Clarimón; Alberto Lleó; Juan Fortea; Ricard Rojas-García Journal: Neurology Date: 2020-09-10 Impact factor: 9.910